Meluha Therapeutics focuses on the development of cellular and gene therapies, including its product candidates Chondrogen and Chondrokin, which are innovative cell therapy products that employ various aspects of developmental platform to treat knee injuries in the scope of orthopaedics, specifically on cartilage damage in the knee.

In the first quarter of 2019, our Phase 1 clinical trial of Chondrogen has met the primary endpoint of a statistically significant improvement in pain and function after the treatment. Based on the significant data, Meluha Life Sciences has initiated a MoU with Hospital Universiti Kebangsaan Malaysia (HUKM) to proceed the clinical path forward for Chondrogen and Chondrokin.



Lot 1G & 2G,
Kompleks Lanai,
No.2, Persiaran Seri Perdana,
62250 Putrajaya, Malaysia.

© Meluha Therapeutics